צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. (IBRX) is implementing AI for molecule design and automating drug synthesis. The LTM sales growth YoY metric demonstrates the current trend, where the 120.80 level indicates the parameter's status. Development relies on a strong scientific staff and large-scale R&D investments, while the commercial success of Anktiva in bladder cancer therapy is actively driving revenue growth.

Year-over-year sales growth (TTM) measures revenue dynamics over a rolling twelve-month period, neutralizing quarterly volatility to assess actual business expansion. This metric allows an investor to differentiate sustainable organic growth from speculative overheating of the asset's value. By analyzing the trend of annual sales volume changes (LTM), one can evaluate the efficiency of scaling operational activities. For ImmunityBio, Inc. (IBRX), this reflects a transition toward autonomy through the development of in-house capacities and a reduction in reliance on external laboratories.